JPMorgan raises Ascendis Pharma target to $167, keeps Overweight
JPMorgan analyst Jessica Fye adjusted the price target for Ascendis Pharma (NASDAQ:ASND), a $7.74 billion biotech company, to $167.00, a slight increase from the previous $165.00, while reiterating ...
WBAL17m
How the Trump administration is working to 'combat' DEI in the private sector
Amid a flurry of executive actions President Trump is taking to dismantle diversity, equity and inclusion (DEI) initiatives ...